AdAlta adalta.com.au


Public lists: Pharma Startups (4732)

Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.

Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.

Company (Alive / Active)

Phone:

Fax:

5959 Cornerstone Court West
Suite 100
San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
AdAlta $0M Nov 30, 2018
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related AdAlta Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Nuon Therapeutics

San Mateo, California, United States
Alive / ActiveNuon Therapeutics discovers novel uses for marketed drugs. The advantage of this approach is that the development program for the marketed indication will have investigated the compounds toxicity and established its tolerability. This makes it possible to proceed directly to clinical trials once the efficacy of the compound has been established in animal models. The costs and risks involved in the drug development process are greatly reduced. Tranilast is under development for the treatment of p...Show allLogin to see details

CSF Therapeutics

Cleveland, Ohio, United States
Alive / ActiveCSF Therapeutics is developing a cerebral blood flow device to prevent neurological debilitation and death, affecting more than 10 million individuals in the US alone, and includes indications such as stroke and Alzheimer's disease. Based on the research at The Cleveland Clinic, CSF Therapeutics' device is designed to increase cerebral blood flow indefinitely without affecting vascular or systemic function.Login to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Binding moieties based on shark ignar domains Jun 02, 2005 Jul 12, 2011 Patent
Binding moieties based on shark ignar domains Feb 16, 2016 Application
Cxcr4 binding molecules Jan 08, 2016 Application